Day: October 31, 2024

KALMAR CORPORATION, STOCK EXCHANGE RELEASE, 31 OCTOBER 2024 AT 15:30 PM (EET) Kalmar Corporation will start to repurchase own shares The Board of Directors of Kalmar Corporation has decided to exercise the authorisation of the Annual General Meeting of Cargotec Corporation on 30 May 2024 to repurchase the company’s own shares. Kalmar will repurchase 250,000 class B shares which are planned to be used as reward payments for Kalmar’s share-based incentive programmes. The shares will be purchased at public trading on Nasdaq Helsinki Ltd. at the market price. The repurchases will start on 4 November 2024 at the earliest. According to the authorisation given to the Board of Directors by Cargotec’s Annual General Meeting, the maximum number of shares that can be acquired is 952,000 class A shares and 5,448,000 class B shares.  On 31 October...

PsyLabs develops and produces certified pharmaceutical-grade nature-derived psychedelics for applications in mental health and well-being Psyence Biomedical has issued common shares to Psyence Group pursuant to a debt-for-equity swap agreement      NEW YORK, Oct. 31, 2024 (GLOBE NEWSWIRE) — Psyence Group Inc. (“Psyence Group“) (CSE: PSYG) today announced the successful closing of its previously announced disposal of its 11.13% stake in privately held PsyLabs to its NASDAQ-listed associate, Psyence Biomedical Ltd (NASDAQ: PBM) (“PBM” or “Psyence Biomed“) (“Disposal“). Per the terms of the Disposal, Psyence Biomed will issue to Psyence Group 2,000,000 shares of its common stock.   PsyLabs is focused on the cultivation and production of psychedelic active pharmaceutical ingredients (APIs)...

The General meeting of shareholders held on 31 October 2024 approved the allocation of the profit of AB Akola Group, which included a pay-out of dividends – 0.03 euro shall be paid for each ordinary registered share. Dividends shall be paid out to persons who were the shareholders of AB Akola Group at the end of the dividend record day – 15 November 2024. The first Ex-Date from which the shares of AB Akola Group (ISIN code LT0000128092) acquired on a regulated market (i.e., a stock exchange) with a settlement cycle of T+2 do not entitle the holder to receive dividends for the financial year 2023/2024 shall be 14 November 2024. The dividends will be paid to the securities account managers of the AB Akola Group shareholders through Nasdaq CSD SE Lithuanian branch. After the deduction of tax, the dividend amount will be transferred...

On 31 October 2024 the Annual General Meeting of Shareholders of AB Akola Group approved Financial Statements, Consolidated Annual Report and Independent Auditor’s Report for the financial year ended 30 June 2024.Key financial indicators Consolidated revenues of the subsidiaries of AB Akola Group (the Group) for the financial year 2023/2024 exceeded EUR 1,506 million and were 25% lower than in the corresponding period of the previous year. The Group sold 3,025 thousand tons of various products, or 18% less than the same period last year. Gross profit increased by 16% to EUR 151 million and operating profit by 36% to EUR 46 million. Consolidated earnings before interest, taxes, depreciation and amortization (EBITDA) amounted to EUR 73.5 million, 18% higher than the previous year. Net profit increased by 74% to EUR 25 million.  2022–2023*2023–2024Change...

MONTREAL, Oct. 31, 2024 (GLOBE NEWSWIRE) — Cerro de Pasco Resources Inc. (CSE: CDPR) (OTCQB: GPPRF) (Frankfurt: N8HP) (“CDPR,” or the “Company”) is pleased to announce that the Company has successfully uplisted from the OTC Pink Market to the OTCQB Venture Market (the “OTCQB”). The Company’s common shares commence trading on the OTCQB today under the trading symbol: GPPRF. Investors will now be able to obtain the latest financial disclosure and Real-Time Level 2 quotes for the Company on  www.otcmarkets.com. The common shares of the Company will continue to trade on the Canadian Securities Exchange under the symbol “CDPR” and the Frankfurt Stock Exchange under the symbol ” N8HP “. Guy Goulet, CEO stated; “We are pleased to begin trading on the OTCQB as it gives our current and potential shareholders another...

Society of Immunotherapy of Cancer (SITC) poster to be presented by collaborator from Memorial Sloan Kettering Cancer Center, Dr. Alan Ho, on November 9, 2024 NEW YORK and VIENNA, Oct. 31, 2024 (GLOBE NEWSWIRE) — HOOKIPA Pharma Inc. (NASDAQ: HOOK) (”HOOKIPA” or the “Company”), a clinical-stage biopharmaceutical company developing next generation immunotherapeutics for the treatment of cancer and serious infectious diseases, today announced that updated Phase 2 data for eseba-vec (HB200) plus pembrolizumab in first-line recurrent/metastatic HPV16-positive head and neck cancer will be presented as a late-breaking poster presentation at the 39th Annual Meeting of the Society for Immunotherapy of Cancer (SITC 2024), taking place in Houston, Texas from November 8-10, 2024. The poster will be presented by Alan Ho, MD, PhD, Chief of the...

LOUISVILLE, Ky., Oct. 31, 2024 (GLOBE NEWSWIRE) — LogicMark, Inc. (NASDAQ: LGMK), a provider of emergency response systems, health communications devices, and technology for the growing personal safety and care economy, will issue a press release announcing its financial results for the third quarter ended September 30, 2024, after the market close on Tuesday, November 12, 2024. Ms. Chia-Lin Simmons, CEO, and Mr. Mark Archer, CFO, will host a live investor call and webcast the same day at 1:30 PM (PST) / 4:30 PM (EST) to review the results. Investors and analysts wishing to participate in the conference call must dial in here: Participant Toll-Free Dials: (800) 715-9871Participant Toll Dials: (646) 307-1963Conference ID: 7663305 To listen to the live webcast, please visit the LogicMark investor relations website or use the link:...

FORT WORTH, TX, Oct. 31, 2024 (GLOBE NEWSWIRE) — Sanara MedTech Inc. Based in Fort Worth, Texas, Sanara MedTech Inc. (“Sanara,” the “Company,” “we,” “our” or “us”) (NASDAQ: SMTI), a medical technology company focused on developing and commercializing transformative technologies to improve clinical outcomes and reduce healthcare expenditures in the surgical, chronic wound and skincare markets, today announced details for the release of its results for the quarter ended September 30, 2024. Sanara will issue its earnings release on Tuesday, November 12, 2024, and will host a conference call on Wednesday, November 13, 2024, at 9:00 a.m. Eastern Time. The toll-free number to call for this teleconference is 888-506-0062 (international callers: 973-528-0011) and the access code is 373459. A telephonic replay of the conference call will...

ATLANTA, Oct. 31, 2024 (GLOBE NEWSWIRE) — Dogwood Therapeutics, Inc. (Nasdaq: DWTX) (the “Company”), formerly Virios Therapeutics, Inc., a clinical‐stage biopharmaceutical company, announced today that it will report third quarter 2024 financial results on Thursday, November 7, 2024 before the open of the financial markets. Management will also host a webcast and conference call on November 7, 2024 at 8:30 a.m. ET to discuss the results and provide a corporate update. The live and archived webcast of the call may be accessed on the Dogwood Therapeutics website under the Investors section: Events and Presentations. The live call can be accessed by dialing 888-506-0062 (domestic) or 973-528-0011 (international) and asking to be connected to the “Dogwood Therapeutics Conference Call” using the access code: 838895. About...

NEW YORK, Oct. 31, 2024 (GLOBE NEWSWIRE) — MiNK Therapeutics (MiNK, NASDAQ: INKT), a clinical-stage company pioneering the development of allogeneic off-the-shelf, invariant natural killer T (iNKT) cell therapies, today announced the appointment of Dr. Robert Kadlec to its Board of Directors. Dr. Kadlec brings unparalleled expertise in biodefense, pandemic preparedness, and public health strategy, positioning MiNK to accelerate its innovative iNKT cell platform for addressing critical infectious diseases, including pathogen-agnostic acute respiratory distress syndrome (ARDS), emerging threats, and immune related diseases. Dr. Kadlec recently served as the U.S. Senate-confirmed Assistant Secretary for Preparedness and Response (ASPR) at the U.S. Department of Health and Human Services (HHS) where he led interagency responses to...